[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ocular-hypertension\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ocular-hypertension":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,26,0,25,[9,41,66,87,111,134,156,178,199,221,243,271,292,306,327,353,379,402,423,453,483,505,539,559,581],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100393358","phase-4-measuring-the-effects-of-netarsudil-latanoprost-and-combination-therapy-on-episcleral-and-retinal-blood-flow-in-ocular-hypertension-and-glaucoma-suspects-100393358",false,"NCT04401982","Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects","Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects Using Erythrocyte Mediated Angiography In Vivo","Inclusion:\n\n* Patients are at least 18 years of age.\n* Patients must have ocular hypertension or be a glaucoma suspect.\n* Patient must not have used any IOP-lowering medication (topical or systemic) within the past 6 months\n* Patients must have open angles on gonioscopy.\n* All patients will have at least one recorded visual field examination within 6 months of enrollment in the study. Visual fields will be assessed using the Hodapp-Andersen-Parish criteria.\n\nExclusion:\n\n* Participation in other investigational studies, unless such participation does not involve the administration of any drugs or agents that could impact the results of this study or have an effect on episcleral flow, as determined by the Investigator.\n* Prior intraocular surgery other than uncomplicated cataract surgery.\n* Allergy or history of adverse reaction to ICG, shellfish, or Iodine.\n* Significant liver disease or uremia.\n* Secondary glaucoma including exfoliation glaucoma, pigmentary glaucoma, or history of acute angle closure.\n* Moderate or severe visual field deficits as per Hodapp-Anderson-Parish criteria.\n* Any condition precluding imaging including reliable visual fields, disc photography, or use of study treatments including media opacity or tilted optic disk\n* Pregnant or nursing patients.","ALL","18 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this clinical trial is to compare participants treated with latanoprost to those treated with Rocklatan (netarsudil\u002Flatanoprost) to determine whether the addition of netarsudil results in greater improvements in episcleral venous blood flow in adults with glaucoma or ocular hypertension. Episcleral venous blood flow will be measured using erythrocyte-mediated angiography (EMA) and laser speckle contrast imaging (LSCI).\n\nThe main questions this study aims to answer are:\n\n* Does Rocklatan produce greater increases in episcleral venous blood flow than latanoprost alone?\n* Can EMA and LSCI reliably detect changes in episcleral venous blood flow following treatment with these medications?\n\nParticipants will:\n\n* Be randomized to receive either latanoprost or Rocklatan\n* Undergo imaging of the episcleral veins using EMA and LSCI before, during, and after treatment, and\n* Complete study visits that include standard ophthalmic examinations and intraocular pressure measurements.\n\nHypothesis: The investigators hypothesize that latanoprost, which primarily increases uveoscleral outflow, will not significantly affect the distal episcleral circulation. In contrast, Rocklatan, through its netarsudil component, is expected to produce measurable increases in episcleral venous flow.",[27,28],"Ocular Hypertension","Suspect Glaucoma","RECRUITING","2026-06-30",{"date":32,"type":33},"2026-07-02","ACTUAL",{"date":32,"type":21},{"date":36,"type":21},"2027-03-17",{"name":38,"class":39},"University of Maryland, Baltimore","OTHER",4,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":65},"100644454","phase-3-kj-tfc-005-phase-3-study-evaluate-the-efficacy-and-safety-of-tfc-003-in-patients-with-primary-open-angle-glaucoma-or-ocular-hypertension-100644454","NCT07662759","[KJ-TFC-005] Phase 3 Study, Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension","A Prospective, Multicenter, Randomized, Investigator-Masked, Active-Controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension","Inclusion Criteria:\n\n1. Male or female adults aged ≥19 years at the time of informed consent.\n2. Diagnosis of primary open-angle glaucoma or ocular hypertension.\n3. At the screening visit, subjects who meet any of the following:\n\n   * history of or current use of triple therapy, or\n   * history of or current use of dual therapy (dorzolamide and a topical beta-blocker), or\n   * inadequate IOP control despite current treatment, and who, in the investigator's judgment, have not achieved target IOP based on the degree of optic nerve damage and may benefit from additional IOP reduction with triple therapy.\n4. Completion of an appropriate washout period for prior glaucoma medications before the randomization visit (based on the longest washout period among the components of prior medications):\n\n   \\- Parasympathomimetics, oral or topical carbonic anhydrase inhibitors: 5 days\n\n   \\- α-agonists: 14 days (brimonidine: 28 days)\n   * β-antagonists, prostaglandin analogues: 28 days\n   * Rho-kinase inhibitors: 28 days\n5. Mean intraocular pressure (IOP) ≥21 mmHg in either eye at 8:30 AM (±1 hour) at the randomization visit (same eye as the study eye).\n6. Ability to understand and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n1\\. Subjects with any of the following comorbidities or conditions:\n\n1. Central visual field defect with mean deviation (MD) ≤ -25 dB on visual field testing.\n2. Chronic, recurrent, or severe inflammatory ocular disease (e.g., scleritis, uveitis, or herpetic keratitis).\n3. Best-corrected visual acuity (BCVA) \\\u003C 0.25 (Han Chun Suk visual acuity chart) at both screening and randomization visits.\n4. Any condition that prevents reliable intraocular pressure (IOP) measurement.\n5. Other ocular pathology that, in the investigator's opinion, precludes use of the investigational product (e.g., severe dry eye).\n6. Conditions requiring additional topical or systemic IOP-lowering medications during the study.\n7. Reactive airway disease, including bronchial asthma or history thereof, bronchospasm, or severe chronic obstructive pulmonary disease.\n8. Sinus bradycardia, second- or third-degree atrioventricular block, overt heart failure, cardiogenic shock, sick sinus syndrome, or sinoatrial block.\n9. Severe renal impairment (creatinine clearance \\\u003C30 mL\u002Fmin) or hyperchloremic acidosis.\n10. Untreated pheochromocytoma.\n11. Any severe disease that, in the investigator's judgment, renders the subject unsuitable for the study.\n\n2\\. History of the following conditions or procedures (including surgery):\n\n1. Ocular trauma or ocular surgery within 24 weeks prior to screening (cataract surgery performed \\>8 weeks prior is not excluded).\n2. Ocular infection or ocular inflammation within 12 weeks prior to screening (within 8 weeks for simple conjunctivitis).\n3. Ocular laser surgery within 12 weeks prior to screening.\n\n3\\. Prior or concomitant medications:\n\n1. Oral beta-blockers within 4 weeks prior to randomization.\n2. Addition of antihypertensive agents that may affect IOP within 4 weeks prior to randomization (excluding beta-blockers; e.g., calcium channel blockers, ACE inhibitors), unless the regimen has been stable for at least 7 days prior to screening.\n3. α-adrenergic agonists, MAO inhibitors, or antidepressants affecting norepinephrine transmission within 2 weeks prior to randomization.\n4. Topical ocular or periocular corticosteroids within 2 weeks prior to randomization.\n5. Systemic corticosteroids within 4 weeks prior to randomization.\n6. Intravitreal or sub-Tenon corticosteroid injection within 24 weeks prior to randomization.\n\n4\\. Subjects requiring contact lens use during the study period. 5. Known hypersensitivity, in the investigator's opinion, to any component of the investigational product or ophthalmic diagnostic eye drops.\n\n6\\. Use of any investigational drug or device within 4 weeks prior to screening (subjects participating in non-interventional studies such as observational studies or PMS may be enrolled).\n\n7\\. Pregnant or breastfeeding women. 8. Women and men of childbearing potential who are unwilling to use medically acceptable contraception or who plan pregnancy during the study period.\n\nAcceptable contraception methods:\n\nHormonal contraceptives (oral, injectable, implantable, etc.) Intrauterine device (IUD) or intrauterine system (IUS) Surgical sterilization (e.g., vasectomy, hysterectomy, bilateral oophorectomy, bilateral salpingectomy) Sexual abstinence (only absolute abstinence is acceptable; periodic abstinence methods such as calendar, basal body temperature, ovulation methods, withdrawal, or barrier methods are not acceptable unless investigator-deemed strict abstinence is appropriate based on age, occupation, lifestyle, or sexual orientation)","19 Years",{"count":50,"type":21},188,[52],"PHASE3","\\[KJ-TFC-005\\] Phase 3 Study, Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension",[55,27],"Glaucoma Open-Angle Primary","2026-06-17",{"date":58,"type":33},"2026-06-23",{"date":60,"type":33},"2025-12-09",{"date":62,"type":21},"2027-06",{"name":64,"class":39},"Kukje Pharma",1,{"id":67,"slug":68,"hasResults":12,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":22,"phases":74,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":65},"100642917","phase-4-imaging-the-effects-of-netarsudil-rhopressa-on-the-trabecular-meshwork-in-glaucoma-and-ocular-hypertension-100642917","NCT07588152","Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension","Adaptive Optics Gonioscopy In Vivo Imaging of the Effects of Rhopressa on the Trabecular Meshwork in Patients With Ocular Hypertension or Glaucoma","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Diagnosis of ocular hypertension or open-angle glaucoma\n* Eye examination within the past year\n* For glaucoma subjects: structural (optic nerve and\u002For retinal nerve fiber layer) and functional (visual field) findings consistent with glaucoma\n* Best-corrected visual acuity of 20\u002F100 or better\n* Open anterior chamber angle as confirmed by gonioscopy and anterior segment optical coherence tomography (AS-OCT)\n* Intraocular pressure between 18 and 34 mmHg (treatment-naïve or after washout, if applicable)\n\nExclusion Criteria:\n\n* Known intolerance to netarsudil ophthalmic solution\n* Corneal scarring or active corneal disease that would interfere with imaging\n* Inability to tolerate gonioscopy procedures\n* Females of childbearing potential who are not using effective contraception or are not sterile\n* Any condition that, in the opinion of the investigator, would place the subject at increased risk or interfere with study completion",{"count":20,"type":21},[24],"This study evaluates the effects of netarsudil (Rhopressa) on the trabecular meshwork in subjects with ocular hypertension or open-angle glaucoma. Participants will be randomized to receive either netarsudil or placebo (artificial tears). High-resolution imaging using adaptive optics gonioscopy, anterior segment optical coherence tomography (AS-OCT), and OCT gonioscopy will be performed at baseline and after approximately 14 days of treatment. The primary objective is to assess changes in trabecular meshwork lamellae spacing, with secondary measures including trabecular meshwork height, width, and Schlemm's canal diameter.",[77,27],"Glaucoma","2026-06-09",{"date":80,"type":33},"2026-06-11",{"date":82,"type":33},"2026-06-05",{"date":84,"type":21},"2028-06",{"name":86,"class":39},"Indiana University",{"id":88,"slug":89,"hasResults":12,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":12,"sex":17,"minAge":94,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":22,"phases":97,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":4},"100643282","phase-1-evaluation-of-the-safety-efficacy-dose-response-of-the-bimatoprost-drug-ring-system-bim-drs-in-pseudophakic-patients-diagnosed-with-open-angle-glaucoma-or-ocular-hypertension-100643282","NCT07641296","Evaluation of the Safety, Efficacy, Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Diagnosed With Open Angle Glaucoma or Ocular Hypertension","Prospective, Multi-Center, Open-Label, Non-Randomized, Multi-Arm Study to Evaluate the Safety, Efficacy, and Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Implanted With a Posterior Chamber Intraocular Lens (PC-IOL) and Diagnosed With Mild to Moderate Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)","Inclusion Criteria:\n\n* Diagnosis of mild to moderate open-angle glaucoma or ocular hypertension\n* Pseudophakic or planned removal of cataract\n* Female participants of childbearing potential must have a negative urine pregnancy test at the baseline visit and agree to the use of contraception\n\nExclusion Criteria:\n\n* Uncontrolled systemic disease\n* History of incisional\u002Frefractive corneal surgery\n* Any glaucoma diagnosis other than OHT, open-angle, or pigmentary glaucoma\n* History of incisional glaucoma surgery\n* Other ocular diseases, pathology, or conditions","22 Years",{"count":96,"type":21},24,[98],"PHASE1","The goal of this clinical trial is to learn if two different doses of the SpyGlass Bimatoprost-Drug Ring System (BIM-DRS) work to treat adult pseudophakic patients with either glaucoma or ocular hypertension. The main question it aims to answer is:\n\nDoes the BIM-DRS lower the pressure inside the eye to treat glaucoma or ocular hypertension?\n\nResearchers will compare two different doses of the BIM-DRS implanted either with a pre-existing commercially available monofocal intraocular lens (IOL) or concurrently with the SpyGlass IOL (IOL with silicone pads (no drug)).\n\nParticipants will:\n\n* Upon providing informed consent and successfully completing the screening visit, stop taking their IOP lowering medications in the eye to be treated.\n* Complete a baseline visit to further evaluate eligibility in the study eye.\n* Undergo surgery to implant the BIM-DRS (BIM-DRS and SpyGlass IOL for Cohorts 3 and 4). Only one eye of each participant will be treated.\n* Complete post-operative follow-up visits for evaluation at Day 1, Week 2, Week 6, Month 3, Month 6, Month 12, Month 18, Month 24, Month 30, and Month 36 (last study visit).",[77,27],"NOT_YET_RECRUITING","2026-06-08",{"date":80,"type":33},{"date":105,"type":21},"2026-07-31",{"date":107,"type":21},"2030-03-31",{"name":109,"class":110},"SpyGlass Pharma, Inc.","INDUSTRY",{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":121,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":4},"100638331","phase-3-efficacy-and-safety-of-dnn3119026-for-ocular-hypertension-or-primary-open-angle-glaucoma-100638331","NCT07617532","Efficacy and Safety of DNN.31.19.026 for Ocular Hypertension or Primary Open-Angle Glaucoma","A Randomized Clinical Trial to Evaluate the Safety and Efficacy of DNN.31.19.026 for the Treatment of Ocular Hypertension or Primary Open-Angle Glaucoma","RENOIR","Inclusion Criteria:\n\n* Participants of either sex, aged ≥18 years;\n* Participants diagnosed with ocular hypertension or primary open-angle glaucoma according to the Clinical Protocol and Therapeutic Guidelines for Glaucoma;\n* Participants requiring ocular hypotensive treatment in one or both eyes, for whom the use of combination topical ocular hypotensive medications is appropriate for intraocular pressure (IOP) reduction.\n\nExclusion Criteria:\n\n* Participants diagnosed with primary open-angle glaucoma with no prior treatment history for the disease;\n* Participants with a cup-to-disc ratio \\>0.8 (horizontal or vertical);\n* Participants with any other clinically significant ocular disease that, in the investigator's opinion, may interfere with the evaluation of study efficacy and safety variables;\n* Participants with ocular infection or inflammation within 3 months prior to the screening\u002Frun-in visit;\n* Participants with a history of trabeculoplasty (within the last 6 months) or surgical procedures for IOP reduction;\n* Participants with a history of ocular surgery within 6 months prior to the screening\u002Frun-in visit;\n* Participants with any corneal abnormality that may affect IOP measurement;\n* Participants with respiratory or pulmonary disorders, such as asthma or chronic obstructive pulmonary disease (COPD);\n* Participants with the following cardiac conditions: sinus bradycardia, sinoatrial block, second- or third-degree atrioventricular block, overt heart failure, or cardiogenic shock;\n* Participants with uncontrolled systemic diseases, such as diabetes, hypertension, chronic hepatic or renal disorders, or any other medical condition that, in the investigator's opinion, may interfere with the investigational product or comparator.",{"count":120,"type":21},336,[52],"This study aims to evaluate the safety and efficacy of DNN.31.19.026 compared with Cosopt® for the treatment of ocular hypertension or primary open-angle glaucoma.",[27,124],"Primary Open Angle Glaucoma","2026-05-25",{"date":127,"type":33},"2026-06-01",{"date":129,"type":21},"2026-06",{"date":131,"type":21},"2028-03",{"name":133,"class":110},"Ache Laboratorios Farmaceuticos S.A.",{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":65},"100617947","phase-4-24-hour-effect-of-rocklatan-compared-with-latanoprost-in-open-angle-glaucoma-and-ocular-hypertension-patients-100617947","NCT07325240","24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients","24-hour Effect Of Rocklatan Compared With Latanoprost In Open Angle Glaucoma And Ocular Hypertension Patients","Inclusion Criteria\n\n* Diagnosis of OHT or mild-to-moderate OAG in both eyes (OAG in one eye and OHT in the fellow eye is acceptable) based on VF, OCT and dilated fundus examination within one year of the screening visit.\n* Both eyes must qualify for the study with an IOP of ≥18 mmHg but ≤34 mmHg on history or at the screening visit\n* Be able and willing to provide signed informed consent and follow study instructions\n* Ability to cooperate with the examinations required for the study and be able to attend all study visits\n* If a contact lens wearer, willing to remove contact lenses at least 24 hours prior to each of the study visits.\n* Best-corrected visual acuity (BCVA) using ETDRS chart of +0.4 logMAR units (Snellen equivalent \\~ 20\u002F50) or better in each eye\n\nExclusion Criteria\n\nOcular:\n\n* Subjects with narrow angles (3 quadrants with Grade 2 or less according to Shaffer Scale), angle closure or a history of angle closure, or peripheral iridotomy in either eye\n* Severe glaucomatous damage\n* Difference in IOP between eyes \\> 4 mmHg (unmedicated) at any baseline time point\n* Use of more than two ocular hypotensive medications within 30 days of screening\n* Chronic or recurrent inflammatory eye diseases in either eye\n* Ocular infection or ocular inflammation in the past 3 months in either eye\n* Ocular trauma other than corneal abrasion within the past 6 months in either eye\n* Clinically significant retinal disease (e.g., severe diabetic retinopathy, exudative or severe non-exudative macular degeneration, macular edema, retinal vein or artery occlusion) in either eye\n* Cornea pathologic changes preventing reliable measurement (e.g., scarring, opacity, edema, keratoconus) in either eye\n* Myopia greater than -6.00D, or hyperopia greater than +2.00D in either eye\n* Central corneal thickness less than 480 μm or greater than 620 μm in either eye\n* Previous intraocular surgery other than routine uncomplicated cataract surgery in either eye\n* Previous glaucoma intraocular surgery or glaucoma laser procedures (except SLT performed more than 6 months ago) in either eye\n* Unilateral intraocular surgery or glaucoma laser procedures\n* Previous corneal refractive surgery in either eye (eg, radial keratotomy, PRK, LASIK, corneal cross-linking, etc.)\n* Severe dry eye in either eye\n* Use of ocular medications in either eye within 30 days of screening, with the exception of IOP-lowering medications (which must be washed out according to the provided schedule), and lubricating drops for dry eye (which may be used throughout the study)\n* Known hypersensitivity to any component of the formulation (eg, benzalkonium chloride, etc.), or to topical anesthetic\n\nSystemic:\n\n* Clinically significant systemic diseases which might interfere with the study\n* Participation in any interventional study within 30 days prior to screening visit\n* Changes of systemic medication that could have an effect on IOP within 30 days prior to screening, or anticipated during the study including, β-adrenergic antagonists, α-adrenergic agonists and antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers\n* Recent change in medications that are known to affect IOP within 30 days prior to the screening visit and during the study including: systemic\u002Finhaled steroids, calcium channel blockers, diuretics, and vasodilators\n* Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control. An adult woman is considered to be of childbearing potential unless she is one year post-menopausal or three months post-surgical sterilization. All females of childbearing potential must have a negative pregnancy test result at the screening examination and must not intend to become pregnant during the study\n* Subjects with a known hypersensitivity or contraindications to any of the ingredients in the study medications",{"count":142,"type":21},30,[24],"The purpose of this study is to evaluate the effect on 24-hour IOP reduction of netarsudil-latanoprost fixed combination in one eye compared to latanoprost alone in the contralateral eye, dosed daily, 1 drop at night (QD, PM) in adult subjects, at least 18 years of age, with open angle glaucoma (OAG) or ocular hypertension (OHT).",[146,27],"Open Angle Glaucoma","2026-04-27",{"date":149,"type":33},"2026-05-01",{"date":151,"type":33},"2025-11-21",{"date":153,"type":21},"2027-10",{"name":155,"class":39},"Mayo Clinic",{"id":157,"slug":158,"hasResults":12,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":22,"phases":165,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":65},"100364366","intraocular-pressure-measured-by-a-novel-sensing-contact-lens-versus-tonometry-100364366","NCT04024293","Intraocular Pressure Measured by a Novel Sensing Contact Lens Versus Tonometry","A Prospective Single Center Open Label Study Assessing Intraocular Pressure Measurements Using a Novel Sensing Contact Lens-based Device as Compared to Standard Tonometry, in Open Angle Glaucoma and Ocular Hypertensive Patients","Inclusion Criteria:\n\n* Informed Consent\n* A clinical diagnosis of primary open angle glaucoma (POAG), including normal tension glaucoma (NTG), for OAG patients\n* A clinical diagnosis of OHT, for OHT patients\n* For all patients:\n\nOpen angles on gonioscopy Aged ≥ 18 years, either gender Both central corneal radii (CCR) between 7.3mm (46.23D) and 8.05mm (41.93D), with a maximum difference of 2D between the 2 radii in the study eye Central corneal thickness (CCT) between 490µm and 600µm in the study eye\n\nExclusion Criteria:\n\n* Ocular pathology (other than glaucoma or OHT)\n* Previous glaucoma, cataract or refractive laser\u002Fsurgery\n* Corneal or conjunctival abnormality, precluding contact lens adaptation\n* Insufficiency of lacrimal secretion\n* Subjects with allergy to corneal anesthetic\n* Subjects with contraindications for silicone contact lens wear\n* Subjects with contraindications for Diamox or Latanoprost or Timolol\n* Skin irritations, skin eczema or other indications against the wearing of adhesive patches\n* Subjects unable or unwilling to comply with the study procedures\n* Subjects lacking the capacity to consent (vulnerable persons)\n* Subjects with history of cardiac failure, treated cardiopathy or renal failure\n* Subjects with known cognitive disorders\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,\n* Participation in another study with investigational drug within the 30 days preceding and during the present study,\n* Enrolment of the investigator, his\u002Fher family members, employees and other dependent persons.",{"count":164,"type":21},12,[166],"NA","While elevated intraocular pressure (IOP) is no longer part of the definition of glaucoma it remains the sole proven modifiable risk factor for the onset and progression of glaucoma.\n\nIOP is known to vary with the time of day as well as with daily activities. The importance of the nycthemeral IOP pattern for successful management of glaucoma has been well documented, especially for patients who experience visual loss despite apparently normal and\u002For controlled IOP during office hours.\n\nThe current way of assessing nycthemeral IOP fluctuation is to perform repeated discrete tonometry measurements, once per hour in the best cases. Since its development in the 50s, Goldmann applanation tonometry (GAT) has remained the gold standard method for measuring IOP, despite its limitations. However, tonometry may be an imperfect method for measuring changes in IOP because it allows only snapshot and non-continuous measurements, it is not physiologic and disturbs the sleep architecture.\n\nThere have been many efforts in the past decades to search for an ambulatory and frequent method to monitor IOP for 24 hours. In this context, Sensimed AG has recently developed a sensing contact lens-based device intended to measure IOP over 24 hours, the Goldfish (GF).\n\nFirst-in-man data obtained with this device showed agreements between IOP measured by GF and values obtained by standard tonometry in the same eye, comparable to literature results for routinely used tonometry devices. However, this pilot study included 9 subjects only with improvable safety, tolerability and efficacy profiles.\n\nThe main goal of this study is to assess IOP measurements with the GF and compare the values with those obtained by standard tonometry in patients with open angle glaucoma (OAG) and ocular hypertension (OHT).",[77,27],"2026-04-24",{"date":171,"type":33},"2026-04-30",{"date":173,"type":33},"2025-10-01",{"date":175,"type":21},"2026-05",{"name":177,"class":110},"Sensimed AG",{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":187,"phases":4,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":65},"100622997","dslt-for-reducing-medication-in-glaucoma-100622997","NCT07390890","DSLT for Reducing Medication in Glaucoma","Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Medication Burden in Medically Controlled Patients With Ocular Hypertension or Primary Open Angle Glaucoma","Inclusion Criteria:\n\n* Adult patients scheduled to undergo DSLT treatment in one or both eyes.\n\n  * Diagnosis of ocular hypertension or primary open angle glaucoma (POAG).\n* Medically controlled on 1-3 topical ocular hypotensive agents with IOP ≤21 mmHg.\n\nExclusion Criteria:\n\n* Previous glaucoma surgeries\u002Finterventions:\n\n  * Patients who have undergone prior glaucoma-related procedures (e.g., trabeculectomy, laser trabeculoplasty, MIGS, or tube shunt).\n* Patients who have undergone cataract surgery within the prior 2 years.\n* Secondary glaucoma:\n\n  * Patients with secondary forms of glaucoma, such as angle-closure glaucoma, neovascular glaucoma, or glaucoma resulting from trauma or other systemic diseases.\n* Other significant ocular conditions including advanced cataracts, retinal diseases (e.g., age-related macular degeneration), or any condition that might complicate the assessment of intraocular pressure (IOP) or visual function as deemed by the investigator.",{"count":186,"type":21},60,"OBSERVATIONAL","This is a prospective, single arm, open label study conducted at a single site to evaluate the efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in reducing medication burden in patients with medically controlled ocular hypertension or primary open angle glaucoma.\n\nThe study will assess the primary endpoint of reduction in medication count at 6 months compared to baseline. Secondary endpoints include IOP reduction compared to baseline (both percentage and absolute), complete success rate (no increase in IOP without medications), proportion of eyes needing medication at 6 months, and any secondary surgical interventions at 6 months post-DSLT.\n\nParticipants will undergo DSLT with 120 shots, 400 µm spot size, and 1.8mJ fixed energy delivered at the limbus over 2.4 seconds. Follow-up visits will occur at 1 month, 3 months, and 6 months post-procedure, with IOP measured using a calibrated Goldmann tonometer.",[124,27],"2026-04-17",{"date":192,"type":33},"2026-04-20",{"date":194,"type":33},"2026-02-10",{"date":196,"type":21},"2027-01-26",{"name":198,"class":39},"The Eye Institute of West Florida",{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":207,"briefSummary":208,"conditions":209,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":65},"100609676","phase-4-biomarkers-of-ocular-surface-damage-in-the-setting-of-topical-ocular-hypotensive-medication-use-100609676","NCT07217678","Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use","Inclusion Criteria:\n\n* Eye with open-angle glaucoma or suspected of open-angle glaucoma\n* Pseudophakic in eye of interest with Shafer grading ≥3\n* ≤ 3 daily applications of topical glaucoma medications for ≥6 months (of which one is a nightly preserved PGA)\n* Good adherence to medication regimen - screening questions to be asked of potential subject:\n* In the last month, what percentage of the time would you estimate missing the application of drops? (Must be ≤20%)\n* When was the last administration? (Last dose must have been within last 24 hours)\n* Presence of punctate epithelial erosions in the cornea (NEI scale \\> 3)\n\nExclusion Criteria:\n\n* Retinal disease (e.g., wet age-related macular degeneration, proliferative diabetic retinopathy, central retinal vein occlusion)\n* Use of topical or systemic immunosuppressor or immunomodulator drug (e.g., steroids, cyclosporine, lifitegrast, or antihistamines)\n* Use of preservative-free hypotensive medications\n* Any clinical contraindications to receiving intracameral bimatoprost implantation\n* History of recurrent conjunctivitis (e.g., allergic or atopic conjunctivitis)\n* History of partial or full corneal transplant\n* History of ophthalmic surgery (intraocular or tarsus-involving oculoplastic procedures) within last 6 months\n* History of subconjunctival glaucoma surgery (i.e., trabeculectomy, aqueous shunt, Xen implant) within last 6 months",{"count":206,"type":21},20,[24],"The objective of this study is to evaluate whether reduction in topical medication with the injection of a sustained release capsule (Durysta) leads to a reduction in ocular surface inflammation, indicated by levels of caspase-1, an inflammatory biomarker.",[77,210,27,211],"Open-Angle Glaucoma","Glaucoma Suspect","2026-03-03",{"date":214,"type":33},"2026-03-05",{"date":216,"type":33},"2026-02-09",{"date":218,"type":21},"2028-01-31",{"name":220,"class":39},"University of Miami",{"id":222,"slug":223,"hasResults":12,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":22,"phases":230,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":65},"100618714","phase-3-efficacy-and-safety-of-huc3-637-in-patients-with-primary-open-angle-glaucoma-or-ocular-hypertension-100618714","NCT07335211","Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension","A Multicenter, Randomized, Single-blind, Active Controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension","Inclusion Criteria:\n\n* Adults aged 19 years and older\n* Participants diagnosed with POAG or OH\n* Have fully explained and understood the study and have voluntarily given written informed consent.\n\nExclusion Criteria:\n\n* Acute or chronic angle-closure glaucoma\n* Congenital glaucoma, secondary glaucoma (open-angle glaucoma)",{"count":229,"type":21},206,[52],"A multicenter, randomized, single-blind, active controlled, phase III clinical trial to evaluate the efficacy and safety of HUC3-637 in patients with primary open angle glaucoma or ocular hypertension",[233,27],"Primary Open Angle Glaucoma (POAG)","2026-01-11",{"date":236,"type":33},"2026-01-13",{"date":238,"type":21},"2026-01",{"date":240,"type":21},"2027-12",{"name":242,"class":110},"Huons Co., Ltd.",{"id":244,"slug":245,"hasResults":12,"nctId":246,"briefTitle":247,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":22,"phases":252,"briefSummary":253,"conditions":254,"keywords":255,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":65},"100564474","implementing-ai-based-glaucoma-screening-within-federally-qualified-health-centers-100564474","NCT06629649","Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers","AI-RONA","Inclusion Criteria:\n\n* African American or Hispanic persons ≥ 40 years old\n* Non-Hispanic white persons ≥ 50 years old\n* Anyone ≥ 18 years old with diabetes type 1 or type 2\n* Anyone ≥ 18 years old who already has a glaucoma associated disease\n* Anyone ≥ 18 years old with a family history of glaucoma\n\nExclusion Criteria:\n\n* Declines to sign written informed consent\n* Cannot communicate in English",{"count":251,"type":21},1800,[166],"The goal of this clinical trial is to learn if implementation of an eye screening program at Federally Qualified Health Center (FQHC) clinics provides results that participants may have glaucoma, and\u002For other eye conditions (diabetic retinopathy, cataract, visual acuity impairment). The glaucoma screening will incorporate use of an artificial intelligence (AI)-assisted screening tool. This project is called AI-RONA. The main questions it aims to answer are:\n\n* How does this eye screening program compare to the rate of glaucoma and other eye conditions detected at other FQHC clinics where the screening program has not been implemented?\n* Do particpants who screen positive for these conditions adhere to the physician's recommendation for a follow-up examination by an optometrist or ophthalmologist?\n* Are referral rates for a follow-up comprehensive eye exam by an optometrist or ophthalmologist similar to those implemented by an ophthalmologist using telemedicine (that is, using the results of the screening to make a diagnosis remotely)?\n* What is the cost-effectiveness of the AI-assisted screening program in diagnosing glaucoma as compared to a physician-guided program?\n* Are participants completing the screening satisfied with it?\n* Are physicians at the FQHC clinics administering the screening satisfied with it?\n\nParticipants will:\n\n* Undergo an ocular screening whose goal is to detect glaucoma, diabetic retinopathy, cataract, and\u002For impairment in visual acuity. If the screening indicates that participants may have these conditions, participants will be referred for a comprehensive eye examination by an optometrist or ophthalmologist.\n* Following the screening, participants and physicians will complete a survey on their satisfaction with the program.",[77,27],[256,257,258,259,260,261],"visual acuity impairment","glaucoma","ocular hypertension","glaucoma suspect","diabetic retinopathy","cataract","2025-12-19",{"date":264,"type":33},"2025-12-29",{"date":266,"type":33},"2025-10-22",{"date":268,"type":21},"2029-09-29",{"name":270,"class":39},"University of Alabama at Birmingham",{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":12,"sex":17,"minAge":94,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":22,"phases":280,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":65},"100609762","phase-3-evaluation-of-the-safety-and-efficacy-of-the-bimatoprost-implant-system-used-in-combination-with-the-spyglass-iol-compared-to-timolol-ophthalmic-solution-rhone-100609762","NCT07218796","Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)","A Prospective, Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety and Efficacy of the Bimatoprost Implant System (78 mcg) Used in Combination With the SpyGlass IOL Compared to Timolol Maleate Ophthalmic Solution, USP, 0.5%,","Inclusion Criteria:\n\n* Diagnosis of mild to moderate open-angle glaucoma or ocular hypertension\n* Planned removal of cataract\n* Female participants of childbearing potential must have a negative urine pregnancy test at the baseline visit and agree to the use of contraception\n\nExclusion Criteria:\n\n* Uncontrolled systemic disease\n* History of incisional\u002Frefractive corneal surgery\n* Any glaucoma diagnosis other than OHT, open-angle, pseudoexfoliative, or pigmentary glaucoma\n* History of incisional glaucoma surgery or intraocular injections\n* Other ocular diseases, pathology, or conditions",{"count":279,"type":21},400,[52],"This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.",[283,77,27],"Cataract","2025-10-16",{"date":286,"type":33},"2025-10-20",{"date":288,"type":21},"2025-10-28",{"date":290,"type":21},"2031-05-31",{"name":109,"class":110},{"id":293,"slug":294,"hasResults":12,"nctId":295,"briefTitle":296,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":12,"sex":17,"minAge":94,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":22,"phases":298,"briefSummary":281,"conditions":299,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":300,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":65},"100609761","phase-3-evaluation-of-the-safety-and-efficacy-of-the-bimatoprost-implant-system-used-in-combination-with-the-spyglass-iol-compared-to-timolol-ophthalmic-solution-rhine-100609761","NCT07218783","Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)",{"count":279,"type":21},[52],[283,77,27],{"date":286,"type":33},{"date":302,"type":33},"2025-10-15",{"date":304,"type":21},"2031-03-31",{"name":109,"class":110},{"id":307,"slug":308,"hasResults":12,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":17,"minAge":314,"maxAge":315,"enrollmentInfo":316,"targetDuration":4,"studyType":187,"phases":4,"briefSummary":317,"conditions":318,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":325,"locationsCount":4},"100609104","glaucoma-diagnostic-and-imaging-analysis-glaudia-study-100609104","NCT07210216","GLAUcoma Diagnostic and Imaging Analysis (GLAUDIA) Study","New Diagnostic Paradigms for the Identification of Early Glaucomatous Damage","GLAUDIA","Inclusion Criteria:\n\n* Age between 40 and 90 years.\n* Best-corrected visual acuity ≥ 0.1 LogMAR (≥ 8\u002F10).\n* For primary open-angle glaucoma (POAG):\n* IOP ≥ 21 mmHg with normal visual field and\u002For normal optic nerve head\u002FRNFL, or\n* Suspicious optic nerve head (excavation), or\n* Reproducible glaucomatous visual field defect.\n* POAG patients stratified by visual field mean deviation (MD): -3 to -10 dB (S1-S2 Brusini classification).\n\nExclusion Criteria:\n\n* Best-corrected visual acuity worse than 0.1 LogMAR (\\\u003C 8\u002F10).\n* Ocular surgery in the last 6 months (except uncomplicated cataract extraction).\n* Previous vitreoretinal surgery for macular pathologies (e.g., macular pucker, macular hole) or retinal detachment.\n* High myopia (\\> -3 diopters).\n* Optic disc anomalies not attributable to glaucoma (tilted disc, papillary drusen, other morphological\u002Ffunctional anomalies).\n* Severe motor disability preventing proper positioning for tests.\n* Cognitive impairment reducing test reliability.","40 Years","90 Years",{"count":186,"type":21},"This observational study aims to identify early diagnostic markers of glaucomatous damage by combining functional and structural assessments. Patients with primary open-angle glaucoma and ocular hypertension will undergo comprehensive ophthalmological evaluation, including visual field testing and multimodal imaging of the optic nerve and retina. Both retrospective and prospective data will be collected. The main objective is to define new diagnostic paradigms for detecting early glaucomatous changes and to improve the accuracy of current clinical practice in glaucoma management.",[55,27],"2025-09-29",{"date":321,"type":33},"2025-10-07",{"date":323,"type":21},"2025-10",{"date":84,"type":21},{"name":326,"class":39},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":328,"slug":329,"hasResults":12,"nctId":330,"briefTitle":331,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":333,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":334,"targetDuration":4,"studyType":187,"phases":4,"briefSummary":336,"conditions":337,"keywords":339,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":65},"100602136","association-between-limbal-function-and-tear-proteomics-in-chronic-ocular-diseases-focusing-on-glaucoma-100602136","NCT07119580","Association Between Limbal Function and Tear Proteomics in Chronic Ocular Diseases: Focusing on Glaucoma","Inclusion Criteria:\n\ni. Age ≥ 18 years. ii. Healthy Control Group: No diagnosis of glaucoma or ocular hypertension. iii. Glaucoma, Newly Diagnosed Group: Diagnosed with angle-closure glaucoma, open-angle glaucoma, or ocular hypertension; antiglaucoma medication usage for less than 3 months.\n\niv. Glaucoma, Long-term Medication Group: Diagnosed with angle-closure glaucoma, open-angle glaucoma, or ocular hypertension; continuous use of intraocular pressure-lowering medications for more than 1 year.\n\nv. Glaucoma, Unilateral Group: Diagnosed with unilateral glaucoma or ocular hypertension; only one eye receiving intraocular pressure-lowering treatment.\n\nExclusion Criteria:\n\ni. History of severe ocular trauma, chemical burns, corneal ulcers, Stevens-Johnson syndrome with ocular involvement, or ocular graft-versus-host disease.\n\nii. History of corneal surgery, conjunctival surgery, trabeculectomy, or glaucoma drainage device implantation.\n\niii. Presence of ocular surface irregularity or limbal dysfunction due to conditions other than glaucoma or dry eye disease.",true,{"count":335,"type":21},90,"Background Intact corneal epithelium is important for the defense on the ocular surface, and the function of limbal stem cells is crucial to maintain its integrity. Certain chronic eye diseases, such as glaucoma, require long-term medication use. However, glaucoma patients often exhibit corneal punctate erosions and ocular surface inflammation. In cases where medication has been used for an extended period, patients may even show symptoms similar to limbal stem cell deficiency. Understanding how glaucoma medications affect the function of corneal limbal stem cells is a critical clinical issue.\n\nObjectives To evaluate the effect of glaucoma and anti-glaucoma agents on corneal epithelial and limbal epithelial thickness as a surrogate of limbal stem cell function, and to understand the association between tear fluid proteome and limbal function in glaucoma patients.\n\nMethods We planned to include 90 subjects with glaucoma, and analyze the absolute thickness and variation of corneal epithelium and limbal epithelium. Tear fluid samples will be collected and proteomic analysis will be performed to elucidate the association between protein.\n\nAnticipated Results To elucidate the impact of different types and cumulative doses of glaucoma medications on the thickness of the corneal epithelium and limbal epithelium, and to understand the relationship between limbal function and tear proteomics in glaucoma patients. The expected results may help develop early detection methods for changes in corneal and limbal epithelial function and provide valuable insights for future research on drug design and the protection of limbal stem cells.",[77,27,338],"Limbal Stem Cell Deficiency",[340,341,77,342,343],"Corneal epithelium","Limbal stem cells","Tear fluid","Proteome","2025-08-06",{"date":346,"type":33},"2025-08-13",{"date":348,"type":33},"2025-07-08",{"date":350,"type":21},"2026-12",{"name":352,"class":39},"National Taiwan University Hospital",{"id":354,"slug":355,"hasResults":12,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":12,"sex":17,"minAge":314,"maxAge":4,"enrollmentInfo":360,"targetDuration":4,"studyType":22,"phases":362,"briefSummary":363,"conditions":364,"keywords":365,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":65},"100595750","phase-1-safety-of-timod-sustained-release-implant-in-participants-with-glaucoma-or-ocular-hypertension-undergoing-cataract-surgery-100595750","NCT07036510","Safety of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract Surgery","Early Feasibility, Open-Label, Dose-Escalating, Non-Randomized Study to Evaluate the Safety of a New Timolol Sustained-Release Intraocular Implant (TimoD) in Participants With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT) Undergoing Cataract Surgery","Inclusion Criteria:\n\n* Capable of giving signed informed consent.\n* In good general and mental health without ongoing clinically significant abnormalities in medical history.\n* Open-angle glaucoma or ocular hypertension and age-related cataract eligible for intra-capsular IOL placement.\n* successful, uncomplicated cataract surgery\n\nExclusion Criteria:\n\n* Subjects with a history of hypersensitivity or contraindications to β- blockers.\n* Participants using any systemic or topical drug known to interfere with visual performance, pupil dilation, or iris structure\n* Significant risks caused by washout of ocular hypotensive medications.\n* Clinically significant ocular pathology other than OHT, glaucoma and cataract",{"count":361,"type":21},18,[98],"The goal of this clinical trial is to test a new method to deliver an approved medicine called Timolol in the eye of participants with glaucoma or ocular hypertension and requiring cataract surgery.\n\nThe main questions it aims to answer are how safe are three different doses of the investigational drug is and how the body tolerates it.\n\nThe study will also check:\n\n* how safely the implant is placed in and removed from the eye and how the body responds to the procedure,\n* if and the amount of Timolol released in the bloodstream,\n* if there is any positive effect on the pressure inside the eye.",[77,27],[77,366,367,283,368,369],"Ocular hypertension","OHT","Timolol","Lens diseases","2025-06-17",{"date":372,"type":33},"2025-06-25",{"date":374,"type":33},"2025-06-12",{"date":376,"type":21},"2027-01",{"name":378,"class":110},"EyeD Pharma",{"id":380,"slug":381,"hasResults":12,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":4,"eligibilityCriteria":385,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":386,"targetDuration":4,"studyType":22,"phases":388,"briefSummary":390,"conditions":391,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":65},"100590190","phase-2-evaluate-efficacy-and-safety-of-pa5108-ocular-implants-in-primary-open-angle-glaucoma-or-ocular-hypertension-100590190","NCT06964191","Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension","A Phase 2 Randomized, Multi-center, Parallel, Active-controlled Clinical Study to Evaluate the Safety and Efficacy of Intracameral PA5108 Ocular Implants in Patients With Primary Open-angle Glaucoma, or Ocular Hypertension","Key Inclusion Criteria:\n\n* Ability to provide informed consent and follow study instructions\n* 18 years of age or older\n* Diagnosis of open-angle glaucoma or ocular hypertension in both eyes\n* Qualifying IOPs across 2 visits following washout of IOP-lowering medication, if applicable\n* Qualifying best-corrected visual acuity BCVA using Early Treatment Diabetic Retinopathy Study (ETDRS) chart in study eye\n* Qualifying corneal endothelial cell density (CEDC) in the study eye\n\nKey Exclusion Criteria:\n\n* Pseudoexfoliation or pigment dispersion, narrow irido-corneal drainage angles, or existing peripheral anterior synechiae in the inferior angle either eye.\n* Advanced or severe glaucoma\n* Disqualifying central corneal thickness in either eye\n* Significant other ocular conditions that could prevent accurate assessment of IOP and corneal health\n* Uncontrolled medical conditions\n* Have previously received, any injectable glaucoma medication into the anterior chamber of the study eye\n* Have received intravitreal injections in the study eye within the last 3 months of the Screening Visit and anticipated need for an intravitreal injection during the course of the study\n* Unwilling or unable to discontinue, in either eye, soft contact lens wear at least 2 days and hard contact lens wear 1 week before scheduled study visits and on implant administration days",{"count":387,"type":21},75,[389],"PHASE2","The goal of this clinical trial is to determine the dose of PA5108 Ocular Implant that is effective and safe for the reduction of intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension, compared to the standard treatment therapy.",[392,27],"Glaucoma, Open-Angle","2025-06-10",{"date":395,"type":33},"2025-06-13",{"date":397,"type":33},"2025-05-31",{"date":399,"type":21},"2026-11-15",{"name":401,"class":110},"PolyActiva Pty Ltd",{"id":403,"slug":404,"hasResults":12,"nctId":405,"briefTitle":406,"officialTitle":406,"acronym":4,"eligibilityCriteria":407,"healthyVolunteers":333,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":408,"targetDuration":4,"studyType":22,"phases":410,"briefSummary":411,"conditions":412,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":65},"100352543","investigation-of-neurovascular-coupling-in-glaucoma-patients-and-healthy-subjects-100352543","NCT03870230","Investigation of Neurovascular Coupling in Glaucoma Patients and Healthy Subjects","Inclusion criteria\n\nPatients with primary open angle glaucoma\n\n* Diagnosis of manifest primary open angle glaucoma defined as pathological optic disc appearance\n* Glaucoma hemifield test outside normal limits\n* Untreated IOP ≥ 21 mmHg on at least three measurements in the medical history\n* Mean deviation in the visual field test is less than or equal 10dB (for one group) OR more than 10dB (for the other group)\n\nPatients with normal tension glaucoma\n\n* Diagnosis of manifest normal tension glaucoma defined as pathological optic disc appearance\n* Glaucoma hemifield test outside normal limits\n* No evidence of untreated IOP \\> 20 mmHg in the medical history\n* Mean deviation in the visual field is less than or equal 10dB (for one group) OR more than 10dB (for the other group)\n\nPatients with ocular hypertension\n\n* Normal ophthalmic findings except presence of ocular hypertension defined as untreated IOP ≥ 21 mmHg on at least three measurements in the medical history\n* No signs of glaucomatous damage in the optic disc\n* or the glaucoma hemifield test\n\nHealthy control subjects\n\n* Normal ophthalmic findings\n* IOP \\\u003C 20 mmHg on least three measurements\n* No evidence of increased IOP in the medical history\n* No signs of glaucomatous damage in the optic disc\n* or the glaucoma hemifield test\n\nExclusion criteria\n\n* History of a severe medical condition as judged by the clinical investigator\n* Abuse of alcoholic beverages\n* Smoker\n* Participation in a clinical trial in the 3 weeks preceding the study\n* Exfoliation glaucoma, pigmentary glaucoma, history of acute angle closure\n* Intraocular surgery within the last 6 months\n* Ocular inflammation or infection within the last 3 months\n* History of epilepsia\n* Diabetes mellitus\n* Untreated hypertension with systolic blood pressure \\> 160 mmHg, diastolic blood pressure \\> 95 mmHg\n* Pregnancy\n* Planned pregnancy or lactating",{"count":409,"type":21},120,[166],"Glaucoma is characterized by a progressive loss of retinal ganglion cells (RGCs) leading to optic nerve head (ONH) damage and associated visual field defects. The main risk factor for glaucoma is elevated intraocular pressure (IOP). Reducing IOP slows down the progression of the disease as several large multicenter trials have shown. Some patients, however, still progress despite adequately controlled IOP. As such, there is considerable interest in approaches that rescue RGCs independent of IOP, a strategy called neuroprotection. Although this field was actively discovered in the last 20 years in the brain and the eye, no non-IOP related treatment is clinically available to date. Various approaches are currently studied in some detail. One interesting strategy focuses on the neurovascular unit.\n\nThe blood flow of the human retina is controlled by complex mechanisms that include myogenic, metabolic and hormonal factors. The high consumption of oxygen in the human retina is crucial for normal functioning of the organ. As in the brain, blood flow in the retina is also controlled by neurovascular coupling. This means that the retina increases its blood flow to regions in which neurons are activated. This is done in an effort to provide more oxygen and glucose to the active neurons. In the recent years evidence has accumulated that astrocytes play a key role in mediating this vasodilator signal.\n\nIn the brain, abnormalities in neurovascular coupling have been observed in diseases like stroke, hypertension, spinal-cord injury and Alzheimer's disease. This break-down of neurovascular coupling is considered to play a key role in neuronal death in these diseases. In the retina, abnormalities in neurovascular coupling have been observed in diseases as diabetes and glaucoma.\n\nMost of the data obtained in the human retina stem from a system that measures retinal vasodilatation during stimulation with flickering light. The investigators have previously shown that flicker stimulation of the retina is, however, also associated with a pronounced increase in retinal blood velocities. In this study the investigators employed laser Doppler velocimetry (LDV) for the measurement of retinal blood velocities, but this technique is not clinically applicable because it requires excellent fixation of the subject under study. In the present study, the investigators propose to use an alternative system for neurovascular coupling that they have developed recently. In this approach, the investigators use bi-directional Fourier-domain optical coherence tomography for the assessment of retinal blood flow. Optical coherence tomography (OCT) is a non-invasive optical imaging modality enabling cross-sectional tomographic in vivo visualization of internal microstructure in biological systems. In ophthalmology, OCT has become a standard tool in visualizing the retina and nowadays is considered also as a standard tool in the diagnosis of retinal disease. In the recent years, conventional time domain OCT was replaced by Fourier domain OCT providing significantly improved signal quality.\n\nThis bidirectional system overcomes the limitations of previously realized techniques, which include doubtful validity and limited reproducibility. In addition, pattern ERG, multifocal ERG and oscillatory potentials will be measured to allow for concomitant assessment of neural function.\n\nThe investigators seek to measure neurovascular coupling in the human retina in patients with early primary open angle glaucoma (POAG), normal tension glaucoma, ocular hypertension and a healthy control group. In order to obtain information on neurovascular coupling, both neuronal function as well as retinal blood flow need to be measured. In the present study, the investigators will employ pattern ERG, multifocal ERG as well as oscillatory potentials to assess the function of the inner retina. Retinal blood flow through major retinal arterial and venous branch vessels will be measured before, during and after flicker stimulation with the dual-beam bidirectional Fourier Domain Doppler OCT coupled to the commercially available Dynamic Vessel Analyzer (DVA) produced by IMEDOS, Jena, Germany, which provides adequate resolution to study the retinal circulation.",[392,413,27],"Normal Tension Glaucoma","2025-05-20",{"date":416,"type":33},"2025-05-23",{"date":418,"type":33},"2017-12-01",{"date":420,"type":21},"2026-03",{"name":422,"class":39},"Medical University of Vienna",{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":12,"sex":17,"minAge":314,"maxAge":315,"enrollmentInfo":430,"targetDuration":4,"studyType":187,"phases":4,"briefSummary":432,"conditions":433,"keywords":438,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":65},"100569231","long-term-safety-and-efficacy-of-a-modified-suprachoroidal-silicone-tube-sst-shunt-100569231","NCT06691555","Long-term Safety and Efficacy of a Modified Suprachoroidal Silicone Tube (SST) Shunt","The Long-term Safety and Efficacy of a Modified Suprachoroidal Silicone Tube (SST) Shunt in Patients with Primary Open-angle Glaucoma (POAG) and Pseudo-exfoliative Glaucoma (PXG) Over an Extended Follow-up Period","Inclusion Criteria:\n\n* Previously were treated with Suprachoroidal silicone tube shunt\n* Willing and able to participate in this cross sectional observational follow up\n* Participant capable of giving informed consent\n\nExclusion Criteria:\n\n* Condition that could impact the ability of the participant to attend a follow-up visit as per the discretion of the investigator",{"count":431,"type":21},66,"The goal of this observational study is to evaluate the long-term safety and efficacy of a modified suprachoroidal silicone tube (SST) shunt in treating patients with primary open-angle glaucoma (POAG) and pseudo-exfoliative glaucoma (PXG).\n\nThe main questions it aims to answer are:\n\nDoes the SST shunt maintain intraocular pressure (IOP) reduction over an extended follow-up period? What is the effect of the SST shunt on endothelial cell count (ECC) and overall corneal health?\n\nParticipants will:\n\nUndergo intraocular pressure (IOP) measurements Have their endothelial cell count (ECC) evaluated Complete assessments of best corrected visual acuity (BCVA) Be assessed for C\u002FD ratio Be monitored for adverse events or shunt-related complications over time",[77,434,435,27,436,437],"Open Angle Glaucoma (OAG)","POAG","Exfoliation Syndrome","Choroidal Effusions",[439,440,77,210,441,442,443],"MIGS","Suprachoroidal Space","Suprachoroidal Silicone Tube","Suprachoroidal Shunt","Glaucoma Shunt","2024-11-14",{"date":446,"type":33},"2024-11-15",{"date":448,"type":33},"2024-11-08",{"date":450,"type":21},"2024-11-30",{"name":452,"class":39},"Davinci LTD",{"id":454,"slug":455,"hasResults":12,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":4,"eligibilityCriteria":459,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":460,"enrollmentInfo":461,"targetDuration":4,"studyType":187,"phases":4,"briefSummary":463,"conditions":464,"keywords":465,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":65},"100442307","inflammatory-biomarkers-in-ocular-surface-in-primary-open-angle-glaucoma-or-ocular-hypertension-under-topical-prostaglandins-100442307","NCT05039684","Inflammatory Biomarkers in Ocular Surface in Primary Open Angle Glaucoma or Ocular Hypertension Under Topical Prostaglandins","Inflammatory Biomarkers in Ocular Surface in Patients With Primary Open Angle Glaucoma and Ocular Hypertension Under Topical Prostaglandin Therapy","Inclusion Criteria:\n\n* Patients with primary open angle glaucoma or ocular hypertension as defined in Early Manifest Glaucoma Trial\n* \\> 18 years old\n* Signed informed consent\n* 3 or more months under monotherapy treatment with tafluprost 0.0015%, latanoprost 0.005% with BAK 0.2mg\u002Fml or latanoprost 0.005%.\n* Untreated patients with ocular hypertension must be treatment naïve for the pathology.\n* No presence or history of previous ocular diseases other than glaucoma or ocular hypertension, started before the use of hypotensive medication.\n\nExclusion Criteria:\n\n* Ocular surgery in the previous 6 months.\n* Any ocular surface disease not related to inclusion criteria or related issues active within the last 6 months.\n* Any topical treatment other than the evaluated in this study in the last 3 months.\n* In case of artificial teardrops use, only non conservative ones are allowed, with no more than 4 times per day use, and treatment must be suspended 5 days before inclusion.\n* Use of contact lenses in the las 4 weeks.\n* Any mental or physical disease that may prevent performing the required tests for the study.","99 Years",{"count":462,"type":21},40,"Glaucoma is a chronic optic neuropathy whose main modifiable risk factor is an abnormally elevated intraocular pressure. The aim of glaucoma treatment is to slow the progression of the disease by reducing intraocular pressure.\n\nProstaglandin derivatives are the most effective topical drugs in reducing intraocular pressure (IOP). Among these, latanoprost was the first agent of this type to be approved for use in patients with glaucoma or ocular hypertension.\n\nThese eye drops are available with and without preservatives. There are two commercial brands in our environment, Xalatan®, which contains 0.005% latanoprost and 0.2 mg\u002Fml benzalkonium chloride (BAK) and Monoprost®, which contains the same amount of latanoprost but does not carry a preservative. The prostaglandin analog with a lower concentration of active ingredient available in Spain without preservative is tafluprost 0.0015%, commercially available under the name Saflutan®.\n\nThe long-term use of hypotensive eye drops with preservatives generates changes in the ocular surface, such as instability of the tear film, conjunctival inflammation, subconjunctival fibrosis, apoptosis of the conjunctival epithelium and deterioration of the corneal surface, causing symptoms such as stinging, tearing, sensation foreign body, photophobia and blurred vision.\n\nThis research will evaluate the changes in the ocular surface and in the expression of inflammatory molecules that occur in the conjunctiva in patients with a diagnosis of glaucoma and ocular hypertension who are under ocular hypotensive treatment with tafluprost, comparing it with the two commercial preparations of latanoprost.\n\nThese three groups of patients will have a control group of patients with a diagnosis of ocular hypertension who will not have any topical hypotensive medication.",[392,27],[257,466,258,467,468,469,470,471,472,473],"prostaglandin","biomarker","inflammation","confocal in-vivo microscopy","cornea","tear film","conjunctiva","impression cytology","2024-10-30",{"date":476,"type":33},"2024-10-31",{"date":478,"type":33},"2021-10-01",{"date":480,"type":21},"2025-12",{"name":482,"class":39},"Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA",{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":4,"eligibilityCriteria":489,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":490,"targetDuration":4,"studyType":22,"phases":492,"briefSummary":493,"conditions":494,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":40},"100536626","phase-1-a-randomized-double-blind-parallel-group-two-arm-multiple-dose-multicenter-bioequivalence-study-with-clinical-endpoint-in-the-treatment-of-subjects-with-chronic-open-angle-glaucoma-or-ocular-hypertension-in-both-eyes-100536626","NCT06267274","A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes","A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint Comparing Generic Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® (Bimatoprost Ophthalmic Solution) 0.01% in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes","Inclusion Criteria:\n\n1. Subjects willing and able to provide voluntary informed consent and to follow protocol requirements.\n2. Male or females aged ≥18 years.\n3. Subjects with chronic open-angle glaucoma or ocular hypertension in both eyes\n4. Subjects requiring treatment of both eyes and able to discontinue the use of all ocular hypotensive medication(s) or switch ocular hypotensive medications and undergo appropriate washout period.\n5. Adequate washout period prior to baseline of any ocular hypotensive medications as (to minimize potential risk to subjects due to intraocular pressure (IOP) elevations during the washout period, the Investigator may choose to substitute a parasympathomimetic or carbonic anhydrase inhibitor in place of a sympathomimetic, alpha-agonist, beta-adrenergic blocking agent, or prostaglandin; however, all the subjects must have discontinued their ocular hypotensive medications for the minimum washout period .\n6. Baseline (Day 0\u002Fhour 0) IOP ≥22 mm Hg and \\\u003C28 mm Hg in each eye, with difference between the IOP in left and right eyes not being more than 5 mm Hg\n7. Subjects' IOP is likely to be controlled with monotherapy as per the Investigator's discretion.\n8. Baseline best corrected visual acuity equivalent to Snellen acuity of 20\u002F100 or better in each eye, using a logarithmic visual acuity chart for testing at 10 feet (3 meters).\n9. Women of childbearing potential (defined as women physiologically capable of becoming pregnant unless they are using an effective method of contraception during the dosing of the study drug) practicing any of the following acceptable methods of contraception:\n\n   1. Oral or parenteral (injection, patch, or implant) hormonal contraception which has been continuously used for at least 1 month prior to first dose of study medication.\n   2. Intrauterine device (IUD) or intrauterine system (IUS)\n   3. Double barrier method of contraception (condom and occlusive cap or condom and spermicidal agent)\n   4. Male sterilization (at least 6 months prior to screening, should be the sole male partner for that subject)\n   5. Female sterilization (surgical bilateral oophorectomy) or tubal ligation at least 6 weeks prior to study participation\n   6. Total abstinence; partial abstinence is not acceptable\n10. No history of addiction to any recreational drug or drug dependence or alcohol addiction\n\nExclusion Criteria:\n\n1. Female who are pregnant, lactating or planning a pregnancy.\n2. Subjects recently diagnosed with open-angle glaucoma or ocular hypertension and who are treatment naive.\n3. Contraindication or known hypersensitivity to Bimatoprost, related class of drugs, or any of the excipients of formulation.\n4. Current or history of severe hepatic or renal impairment.\n5. Current or history within 2 months prior to baseline of any other significant ocular disease, e.g., corneal edema, uveitis, ocular infection, or ocular trauma in either eye (Note: stable myopia, strabismus, and cataracts as per the Investigator's discretion will be allowed provided that the other inclusion\u002Fexclusion criteria are met).\n6. Current corneal abnormalities that would prevent accurate IOP readings with Goldmann applanation tonometer.\n7. Functionally significant visual field loss in the Investigators' opinion.\n8. Subject with corneal grafts.\n9. Subject has contraindication to pupil dilation.\n10. Use at any time prior to baseline of an intraocular corticosteroid implant.\n11. Use of contact lens within 1 week prior to baseline.\n12. Use within 2 weeks prior to baseline of 1) a topical ophthalmic corticosteroid or 2) a topical corticosteroid.\n13. Use within 1 month prior to baseline of 1) a systemic corticosteroid or 2) high-dose salicylate therapy defined as 325 mg\u002Fday and taken on 3 consecutive days.\n14. Use within 6 months prior to baseline of intravitreal or subtenon injection of an ophthalmic corticosteroid.\n15. Underwent within 6 months prior to baseline any other intraocular surgery (e.g., cataract surgery).\n16. Underwent within 12 months prior to baseline any refractive surgery, filtering surgery, or laser surgery for IOP reduction (e.g., laser trabeculoplasty).\n17. Amblyopia - only one sighted eye.\n18. Subjects with a history of IOP previously uncontrolled on bimatoprost monotherapy.\n19. Significant ocular surface findings (e.g., hyperemia or irritation, mild or greater) in either eye found on gross macroscopic or slit lamp examination.\n20. Severe retinal disease or other severe ocular pathology, such as glaucomatous damage with a cup\u002Fdisk ratio greater than 0.8 (not including physiological cupping in the Investigators' opinion) or split fixation.\n21. Chronic use of any systemic medication that may affect IOP with less than 3 months stable dosing regimen (i.e., sympathomimetic agents, beta-adrenergic blocking agents, alpha-agonists, alpha-adrenergic blocking agents, calcium channel blockers, angiotensin-converting enzyme inhibitors, etc.)\n22. Central Corneal thickness (CCT) \\\u003C450 microns or \\>650 microns.\n23. Known history or presence of any uncontrolled systemic disease (e.g., cardiovascular disease, hypertension, diabetes mellitus, hepatic impairment, etc.)\n24. History of recurrent ocular seasonal allergies within the past 2 years.\n25. Any other medical condition or serious intercurrent illness that, in the Investigator's opinion, may make it undesirable for the subject to participate in the study and would limit adherence to the study requirements.\n26. Participation in any clinical study within 30 days before the first dose of the study drug.\n27. Subjects with known history of positive serology for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV) infection.\n28. Subjects with positive urine pregnancy test.",{"count":491,"type":21},240,[98],"A randomized, double-blind, parallel-group, two-arm, multiple dose, multicenter, clinical endpoint bioequivalence study",[495,27],"Open-angle Glaucoma","2024-08-05",{"date":498,"type":33},"2024-08-06",{"date":500,"type":33},"2024-04-01",{"date":502,"type":21},"2025-05-01",{"name":504,"class":110},"Amneal Pharmaceuticals, LLC",{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":511,"eligibilityCriteria":512,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":513,"targetDuration":4,"studyType":22,"phases":515,"briefSummary":516,"conditions":517,"keywords":519,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":65},"100554388","phase-4-efficacy-of-nsaid-vs-steroid-nsaid-combo-post-selective-laser-trabeculoplasty-phase-4-single-center-rct-100554388","NCT06498440","Efficacy of NSAID vs. Steroid-NSAID Combo Post-Selective Laser Trabeculoplasty: Phase 4, Single-Center RCT","Comparative Efficacy of NSAID and Steroid-NSAID Combination Following Selective Laser Trabeculoplasty: a Phase 4, Single-centre, Randomized Controlled Trial","CES-NSLT","Inclusion Criteria:\n\n* Adults aged 18 years and older.\n* Diagnosed with open-angle glaucoma.\n* Intraocular pressure (IOP) greater than 16 mmHg on at least two consecutive occasions separated by one month.\n* Visual acuity of 20\u002F200 or better in at least one eye.\n* Provided informed consent.\n\nExclusion Criteria:\n\n* Patients with any other ocular disorders or surgeries within the last six months.\n* Allergy or intolerance to ketorolac or fluorometholone.\n* Previous use of systemic ketorolac or fluorometholone in the past month.\n* Pregnancy or breastfeeding.\n* Patients who are unable to speak\u002Funderstand English.\n* Any condition that in the investigator's opinion would make participation not in the best interest of the patient or could prevent, limit, or confound the protocol-specified assessments.",{"count":514,"type":21},126,[24],"This clinical trial, led by Dr. Enitan A. Sogbesan at the Hamilton Regional Eye Clinic, St. Joseph's Healthcare Hamilton, aims to compare the efficacy and safety of non-steroidal anti-inflammatory drug (NSAID) ketorolac alone versus a combination of ketorolac and the corticosteroid fluorometholone, and a control group receiving no postoperative treatment. The trial will evaluate these treatment strategies following Selective Laser Trabeculoplasty (SLT) in patients with open-angle glaucoma. The primary objective is to determine the most effective postoperative management strategy to reduce inflammation, improve patient comfort, and control intraocular pressure (IOP). Participants will be randomly assigned to one of the three groups, with follow-up visits scheduled at 1 hour, 1 week, 1 month, 3 months, 6 months, and 1 year post-SLT. The study's findings aim to guide clinicians in optimizing postoperative care for better patient outcomes.",[146,27,518],"Postoperative Inflammation",[520,521,522,523,524,525,526,527,528,529],"Selective Laser Trabeculoplasty (SLT)","Non-steroidal anti-inflammatory drugs (NSAIDs)","Ketorolac","Fluorometholone","Postoperative care","Intraocular pressure (IOP)","Visual acuity","Glaucoma treatment","Ophthalmology","Randomized controlled trial (RCT)","2024-07-05",{"date":532,"type":33},"2024-07-12",{"date":534,"type":21},"2024-09-01",{"date":536,"type":21},"2025-07-01",{"name":538,"class":39},"St. Joseph's Healthcare Hamilton",{"id":540,"slug":541,"hasResults":12,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":315,"enrollmentInfo":546,"targetDuration":4,"studyType":187,"phases":4,"briefSummary":548,"conditions":549,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":553,"completionDateStruct":555,"leadSponsor":557,"locationsCount":4},"100551099","the-a-d-a-g-i-o-study-100551099","NCT06455683","The A D A G I O Study","The Effect of Glaucoma Surgery on Aqueous Dynamics in Patients With Glaucoma or Ocular Hypertension","Inclusion Criteria:\n\n* Males or females between the ages of 18 and 90 (inclusive).\n* Able to understand the study and give informed consent.\n* Willing, able and available to participate in the study. If Flurophotometer test required must not have had prior cataract surgery.\n* Diagnosis of glaucoma or OHT which requires glaucoma surgery (trans-trabecular meshwork surgery with or without an implant, trans-scleral surgery with or without implant, ciliary body treatment, suprachoroidal surgery with or without implant, external non-incisional treatment). (Defined as primary or secondary glaucoma; all types of secondary glaucoma may be included. Glaucoma will be diagnosed based on abnormal visual field testing and corresponding disc changes once seen by a glaucoma specialist.)\n* It is judged clinically safe for the patient to undergo treatment washout (stop taking glaucoma drops).\n\nExclusion Criteria:\n\n* Diagnostic criteria for inclusion not met.\n* Allergy to fluorescein.\n* It is judged as not clinically safe or patient is not willing to undergo treatment washout (stop taking glaucoma drops).\n* Current use of any investigational drug or device or current participation in an interventional clinical trial\u002Fstudy.\n* Participants in the study must be able to understand English to complete some of the tests so those who might not adequately understand written information or verbal explanations in English will not be included",{"count":547,"type":21},150,"This study aims to investigate the effect of different types of glaucoma surgery on aqueous dynamics parameters (IOP, aqueous flow rate, trabecular outflow facility and uveoscleral outflow) in patients with uncontrolled open angle glaucoma or ocular hypertension (OHT)",[146,27],"2024-06-07",{"date":552,"type":33},"2024-06-12",{"date":554,"type":21},"2024-06",{"date":556,"type":21},"2029-06",{"name":558,"class":39},"Guy's and St Thomas' NHS Foundation Trust",{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":4,"eligibilityCriteria":565,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":566,"targetDuration":4,"studyType":22,"phases":568,"briefSummary":569,"conditions":570,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":580},"100435984","phase-4-effect-of-benzalkonium-chloride-preserved-and-preservative-free-latanoprost-eye-drops-on-conjunctival-goblet-cells-100435984","NCT04957329","Effect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on Conjunctival Goblet Cells","Department of Ophthalmology, Rigshospitalet-Glostrup Valdemar Hansens Vej 13, 2600 Glostrup, Denmark","Inclusion Criteria:\n\n1. Age \\>18years\n2. Danish speaking\n3. Open angle glaucoma or ocular hypertension\n4. Average intraocular pressure equal to or above 22 mmHg\n\nExclusion Criteria:\n\na. history of significant eye diseae (including okular trauma) other than open angle glaucoma and ocular hypertension d. treatment with steroids within the last 3 months from inclusion e. Significant untreated systemic disease such as hypertension, heart failure, diabetes mellitus, stroke, lung disease and autoimmune diseases. Diseases are not reason for exclusion if they are well treated or does not need treatment g. pregnant or breast feeding h. women using unsafe anticonception i. allergy towards trial medication j. patients who cannot cooperate in eye examination k. ocular surface defects l. need for polytherapy in glaucoma treatment",{"count":567,"type":21},28,[24],"a randomized, investigator-blind, interventinal study will compare the effect of benzalkonium-chloride (BAK) preserved and preservative-free (PF) eye drops on conjunctival goblet cells.",[77,27],"2023-11-15",{"date":573,"type":33},"2023-11-18",{"date":575,"type":33},"2021-09-01",{"date":577,"type":21},"2026-12-31",{"name":579,"class":39},"Rigshospitalet, Denmark",2,{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":585,"acronym":4,"eligibilityCriteria":586,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":587,"targetDuration":4,"studyType":22,"phases":588,"briefSummary":589,"conditions":590,"keywords":591,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":601,"locationsCount":65},"100504138","nanodropper-use-in-primary-open-angle-glaucoma-patients-a-non-inferiority-trial-100504138","NCT05844384","Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial","Inclusion Criteria:\n\n* POAG\u002FOHTN patients above the age of 18 years.\n* On a maximum of 2 IOP lowering medications.\n* Stable disease without progression in IOP, optic disc cupping, RNFL changes, and visual field changes within the previous 1 year.\n\nExclusion Criteria:\n\n* Glaucoma not of the POAG or OHTN variety or other retinal diseases.\n* Progression of disease within the preceding 1 year (IOP elevation, optic disc cupping, visual field changes).\n* Using more than 2 IOP-lowering medications.\n* IOP-lowering surgical interventions or lasers except for SLT. SLT may have been completed 6+ months prior to study start date.",{"count":142,"type":21},[166],"This randomized, single-masked, crossover, non-inferiority trial aims to evaluate the safety and efficacy of Nanodropper-mediated microdrops of ocular hypotensive topical treatments (experimental intervention) compared to standard drops of the same medication(s) (active comparator) in Wilford Hall Ambulatory Surgical Center (WHASC) primary open-angle glaucoma (POAG) and ocular hypertension (OHTN) patients.",[27,124],[592,124,593,27],"Nanodropper","Microdrops","2023-05-03",{"date":596,"type":33},"2023-05-06",{"date":598,"type":33},"2022-03-17",{"date":600,"type":21},"2024-03-17",{"name":602,"class":603},"59th Medical Wing","FED"]